Cagrilintide: difference between revisions
Diff·revision 4 → 5·02:12, 23 Sep 2024
Difference between revision 4 and revision 5 of Cagrilintide. 2 lines changed; the page grew by 215 bytes.
| Revision 4 — 13:29, 6 Sep 2024 SemaglutideSasha (talk) the lead claimed weekly dosing for a compound dosed daily; corrected 1,887 bytes ±0 | Revision 5 — 02:12, 23 Sep 2024 IcodecIndra (talk) correct the dose ladder — the maintenance dose is not the maximum dose 2,102 bytes +215 | ||
|---|---|---|---|
| 11 | Its actions follow those of amylin: slowed [[Gastric emptying|gastric emptying]], suppression of postprandial glucagon, and reduced food intake through hindbrain circuits distinct from the [[GLP-1 receptor|GLP-1]] pathway.{{r|hay2015}} | 11 | Its actions follow those of amylin: slowed [[Gastric emptying|gastric emptying]], suppression of postprandial glucagon, and reduced food intake through hindbrain circuits distinct from the [[GLP-1 receptor|GLP-1]] pathway.{{r|hay2015}} |
| 12 | 12 | ||
| + | 13 | It is studied principally in combination with [[Semaglutide|semaglutide]] as [[CagriSema]], on the rationale that the two satiety mechanisms are additive. It is not approved for use in any indication.{{r|lau2021}} | |
| + | 14 | ||
| 13 | == Design == | 15 | == Design == |
| 14 | The engineering problem is the same one pramlintide solved differently. Human amylin forms fibrils at concentrations well below those a formulation requires, so a developable analogue must break the β-sheet propensity of the central region while retaining receptor activity.{{r|hay2015}} | 16 | The engineering problem is the same one pramlintide solved differently. Human amylin forms fibrils at concentrations well below those a formulation requires, so a developable analogue must break the β-sheet propensity of the central region while retaining receptor activity.{{r|hay2015}} |